<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-99997</identifier>
<setSpec>0025-7753</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Comparison of restenosis rate of bare-metal and drug-eluting stents in cardiac allograft vasculopathy</dc:title>
<dc:description xml:lang="en">Background and objective: To assess whether there are differences in the rate of restenosis between bare metal stents (BMS) and drug eluting stents (DES) implanted for the treatment of cardiac allograft vasculopathy (CAV). Patients and methods:  This retrospective study describes the baseline characteristics, clinical and angiographic evolution of a sample of heart transplant patients treated with coronary stent implantation due to CAV. Results: We analyzed the follow-up of 40 stents (17 BMS and 23 DES). Mean follow-up was 28±18 months (range 12 to 84). The DES group had a lower rate of active smoking, a higher percentage of residual stenosis and an increased use of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers. Control angiography was performed in 33 stents (82%). In the BMS group (n=15), 8 restenosis were identified (53%) whereas 2 (11%) were seen in the DES group (n=18) (P=.02). Conclusion: In this series a lower rate of restenosis was observed in the DES group, attributable to the effect of the drug released locally by the stent (AU)</dc:description>
<dc:creator>Bayés-Genís, Antoni</dc:creator>
<dc:creator>Cardona, Montserrat</dc:creator>
<dc:creator>Sabaté, Manel</dc:creator>
<dc:creator>Martín, Victoria</dc:creator>
<dc:creator>Martí, Vicenç</dc:creator>
<dc:creator>Mirabet, Sonia</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Fundamento y objetivo: Evaluar si existen diferencias en la tasa de reestenosis entre stents convencionales (SC) y stents farmacoactivos (SFA) implantados para el tratamiento de la enfermedad vascular del injerto (EVI).Pacientes y método: Estudio retrospectivo que describe las características basales, evolución clínica y angiográfica de una muestra de pacientes con trasplante cardíaco y EVI sometidos a implantación de stents coronarios. Resultados: Se analizó el seguimiento de 40 stents (17 SC y 23 SFA), siendo este de media (DE) de 28 (18) meses (extremos 12 a 84). El grupo SFA presentaba menor tasa de tabaquismo activo, mayor porcentaje de estenosis residual y mayor uso de inhibidores de la enzima conversora de la angiotensina/antagonistas del receptor de la angiotensina de tipo II. Se realizó control angiográfico de 33 stents (82%). En el grupo SC (n=15) se identificaron 8 reestenosis (53%) y 2 (11%) en el grupo SFA (n=18) (p=0,02). Conclusión: En esta serie se observa menor tasa de reestenosis en el grupo de SFA, atribuible al efecto del fármaco liberado localmente por el stent (AU)</dc:description>
<dc:source>Med. clín (Ed. impr.);138(13): 562-564, mayo 2012. tab</dc:source>
<dc:identifier>ibc-99997</dc:identifier>
<dc:title xml:lang="es">Comparación de la tasa de reestenosis entre stents convencionales y stents farmacoactivos en la enfermedad vascular del injerto</dc:title>
<dc:subject>^d23925^s22020</dc:subject>
<dc:subject>^d28612</dc:subject>
<dc:subject>^d6234^s22080</dc:subject>
<dc:subject>^d29419</dc:subject>
<dc:subject>^d52881^s22074</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d23232^s22074</dc:subject>
<dc:type>article</dc:type>
<dc:date>201205</dc:date>
</metadata>
</record>
</ibecs-document>
